Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-38633 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-Phospho-IRAK1 (Thr209) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- -20°C
Submitted references Myeloid Differentiation Primary Response 88-Cyclin D1 Signaling in Breast Cancer Cells Regulates Toll-Like Receptor 3-Mediated Cell Proliferation.
Singh A, Devkar R, Basu A
Frontiers in oncology 2020;10:1780
Frontiers in oncology 2020;10:1780
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Phospho-IRAK1 pThr209 in extracts from HeLa cells using a Phospho-IRAK1 pThr209 polyclonal antibody (Product # PA5-38633).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Western blotting for the expression of signaling protein. (A,B) Cell lysate were collected and subjected to Western blot assay to estimate the level of expression of interleukin 1 receptor-associated kinase 1 (IRAK1), transforming growth factor beta-activated kinase 1 (TAK1), TGF-beta-activated kinase 1 (TAB1), TNF receptor-associated factor 6 (TRAF6), and cyclin D1. (C,D) Expression of pIRAK1 and pTAK1. beta-actin was used as loading control. The respective bar graphs are presented as densitometry analysis as mean +- SD of experiments ( p < 0.05 is treated as significant).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 Immunoprecipitation showing the involvement of the signaling complex. (A) Signaling complex of IRAK1/TRAF6 was immunoprecipitated with antibodies against IRAK1 followed by Western blotting with anti-TRAF6 and anti-IRAK1 antibodies. (B) Signaling complex of pIRAK1/TAK1 was immunoprecipitated with antibodies against pIRAK1 followed by Western blotting with anti-TAK1 and anti-pIRAK1 antibodies. (C) Signaling complex TAB1-TRAF6-TAK1 was immunoprecipitated with antibodies against pTAK1 followed by Western blotting using anti-TRAF6, TAB1, and pTAK1 antibodies. (D) Signaling complex TAB1-TRAF6-TAK1 was immunoprecipitated with antibodies against TRAF6 followed by Western blotting analysis using anti-TAK1, TAB1, and TRAF6 antibodies.